Characterization of Botulinum Neurotoxin Type A Neutralizing Monoclonal Antibodies and Influence of Their Half-Lives on Therapeutic Activity

Christelle Mazuet, Julie Dano, Michel R. Popoff et al. · 2010

Read Characterization of Botulinum Neurotoxin Type A Neutralizing Monoclonal Antibodies and Influence of Their Half-Lives on Therapeutic Activity by Christelle Mazuet, Julie Dano, Michel R. Popoff et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0012416.txt.

Description

Christelle Mazuet, Julie Dano, Michel Popoff and colleagues built antibodies against botulinum toxin type A, in a 2010 PLOS ONE paper. Botulinum toxins are among the most poisonous substances known, and botulism can paralyze and kill. Antibodies that neutralize the toxin are the main treatment, and how long they last in the body shapes how well they work.

The team characterized several neutralizing monoclonal antibodies and tested how their half-lives affected treatment success. Longer-lasting antibodies protected better in their tests. The work guides design of antibody therapies that can be stockpiled for outbreaks, whether natural, accidental, or deliberate, where rapid treatment saves lives.

Catalog record

CREATORChristelle Mazuet, Julie Dano, Michel R. Popoff et al.
YEAR2010
COLLECTIONPAPERS
FORMATTXT
FILE SIZE49 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0012416

Browse the full library · About the Tower of Babel